RSS-Feed abonnieren
DOI: 10.1055/s-0041-1740540
Bacterial Spectrum and Infective Foci in Patients Operated for Infective Endocarditis: Time to Rethink Strategies?
![](https://www.thieme-connect.de/media/thoracic/202301/lookinside/thumbnails/10-1055-s-0041-1740540_216191oc-1.jpg)
Abstract
Objective The rising incidence of infective endocarditis (IE) accompanied by the de-escalation of antibiotic prophylaxis and the complexity of surgical treatment makes IE a daunting foe. We reviewed all patients who underwent cardiac surgery for IE at our institution with a focus on causative organisms and infective foci.
Methods A review of 3,952 consecutive patients who underwent cardiac surgery at our institution between January 2013 and December 2017 revealed 160 patients (4%) who were operated for IE.
Results The predominantly affected valves were the aortic (30%) and mitral valve (26.9%) as well as a combination of both (8.8%). A total of 28.8% of patients suffered from prosthetic valve endocarditis (PVE). The most frequently identified causative organisms were Staphylococcus (45.7%), Streptococcus (27.5%), and Enterococcus species (16.7%), which was predominantly associated with PVE (p = 0.050). In 13.1% of patients, a causative organism has not been detected. The most frequent infective foci were dental (15%), soft-tissue infections (15%), spondylodiscitis (10%), and infected intravascular implants (8.8%). Relevant predisposing factors were immunosuppression (9.4%) and intravenous drug abuse (4.4%). Septic cerebral infarctions were diagnosed in 28.8% of patients. Postoperative mortality was 22.5%.
Conclusions As the bacterial spectrum and the infective foci are still the “old acquaintances,” and with regard to the increasing incidence of IE, current risk–benefit evaluations concerning antibiotic prophylaxis may need to be revisited.
Authors' Contributions
Shekhar Saha Data curation, formal analysis, visualization, writing – original draft and revisions
Anna Dudakova Data curation, methodology, validation
Bernd Danner Project administration, validation
Ingo Kutschka Project administration, validation
Marco Schulze* Conceptualization, formal analysis, investigation, methodology, writing – original draft and revisions
Heidi Niehaus* Conceptualization, formal analysis, investigation, methodology, writing – original draft and revisions
* M. H. S. and H. N. contributed equally to the manuscript.
Publikationsverlauf
Eingereicht: 31. Januar 2021
Angenommen: 25. Oktober 2021
Artikel online veröffentlicht:
08. Februar 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Cahill TJ, Prendergast BD. Infective endocarditis. Lancet 2016; 387 (10021): 882-893
- 2 Naber CK. Paul-Ehrlich-Gesellschaft für Chemotherapie, Deutschen Gesellschaft für Kardiologie, Herz- und Kreislaufforschung, Deutschen Gesellschaft für Thorax-, Herz- und Gefässchirurgie, Deutschen Gesellschaft für Infektiologie, Deutschen Gesellschaft für Internistische Intensivmedizin und Notfallmedizin, Deutschen Gesellschaft für Hygiene und Mikrobiologie. S2 Guideline for diagnosis and therapy of infectious endocarditis [in German]. Z Kardiol 2004; 93 (12) 1005-1021
- 3 Habib G, Lancellotti P, Antunes MJ. et al; ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36 (44) 3075-3128
- 4 Habib G, Hoen B, Tornos P. et al; ESC Committee for Practice Guidelines, Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J 2009; 30 (19) 2369-2413
- 5 Danchin N, Duval X, Leport C. Prophylaxis of infective endocarditis: French recommendations 2002. Heart 2005; 91 (06) 715-718
- 6 Wilson W, Taubert KA, Gewitz M. et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, American Heart Association Council on Cardiovascular Disease in the Young, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Cardiovascular Surgery and Anesthesia, Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116 (15) 1736-1754
- 7 Richey R, Wray D, Stokes T. Guideline Development Group. Prophylaxis against infective endocarditis: summary of NICE guidance. BMJ 2008; 336 (7647): 770-771
- 8 Thornhill MH, Gibson TB, Cutler E. et al. Antibiotic prophylaxis and incidence of endocarditis before and after the 2007 AHA recommendations. J Am Coll Cardiol 2018; 72 (20) 2443-2454
- 9 Sakai Bizmark R, Chang RR, Tsugawa Y, Zangwill KM, Kawachi I. Impact of AHA's 2007 guideline change on incidence of infective endocarditis in infants and children. Am Heart J 2017; 189: 110-119
- 10 Rajani R, Klein JL. Infective endocarditis: a contemporary update. Clin Med (Lond) 2020; 20 (01) 31-35
- 11 Li JS, Sexton DJ, Mick N. et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30 (04) 633-638
- 12 Nashef SAM, Roques F, Sharples LD. et al. EuroSCORE II. Eur J Cardiothorac Surg 2012; 41 (04) 734-744 , discussion 744–745
- 13 Levy B, Bastien O, Karim B. et al. Experts' recommendations for the management of adult patients with cardiogenic shock. Ann Intensive Care 2015; 5 (01) 52
- 14 Arrowsmith JE, Grocott HP, Reves JG, Newman MF. Central nervous system complications of cardiac surgery. Br J Anaesth 2000; 84 (03) 378-393
- 15 Lamy B, Dargère S, Arendrup MC, Parienti JJ, Tattevin P. How to optimize the use of blood cultures for the diagnosis of bloodstream infections? A state-of-the art. Front Microbiol 2016; 7: 697
- 16 Otto CM, Nishimura RA, Bonow RO. et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143 (05) e72-e227
- 17 Lamy B, Sundqvist M, Idelevich EA. ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES). Bloodstream infections - standard and progress in pathogen diagnostics. Clin Microbiol Infect 2020; 26 (02) 142-150
- 18 Greisen K, Loeffelholz M, Purohit A, Leong D. PCR primers and probes for the 16S rRNA gene of most species of pathogenic bacteria, including bacteria found in cerebrospinal fluid. J Clin Microbiol 1994; 32 (02) 335-351
- 19 Loeffler J, Henke N, Hebart H. et al. Quantification of fungal DNA by using fluorescence resonance energy transfer and the light cycler system. J Clin Microbiol 2000; 38 (02) 586-590
- 20 Keller K, von Bardeleben RS, Ostad MA. et al. Temporal trends in the prevalence of infective endocarditis in Germany between 2005 and 2014. Am J Cardiol 2017; 119 (02) 317-322
- 21 Baumgartner H. Endokarditisprophylaxe nach den neuen Guidelines der Europäischen Kardiologischen Gesellschaft. J Kardiol 2011; 18: 9-11
- 22 Habib G, Erba PA, Iung B. et al; EURO-ENDO Investigators. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J 2019; 40 (39) 3222-3232
- 23 Tornos P, Iung B, Permanyer-Miralda G. et al. Infective endocarditis in Europe: lessons from the Euro heart survey. Heart 2005; 91 (05) 571-575
- 24 Murdoch DR, Corey GR, Hoen B. et al; International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009; 169 (05) 463-473
- 25 Hoen B, Alla F, Selton-Suty C. et al; Association pour l'Etude et la Prévention de l'Endocardite Infectieuse (AEPEI) Study Group. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA 2002; 288 (01) 75-81
- 26 Luehr M, Bauernschmitt N, Peterss S. et al. Incidence and surgical outcomes of patients with native and prosthetic aortic valve endocarditis. Ann Thorac Surg 2020; 110 (01) 93-101
- 27 Prendergast BD. Diagnostic criteria and problems in infective endocarditis. Heart 2004; 90 (06) 611-613
- 28 Cahill TJ, Baddour LM, Habib G. et al. Challenges in infective endocarditis. J Am Coll Cardiol 2017; 69 (03) 325-344
- 29 Pizzi MN, Roque A, Fernández-Hidalgo N. et al. Improving the diagnosis of infective endocarditis in prosthetic valves and intracardiac devices with 18F-fluordeoxyglucose positron emission tomography/computed tomography angiography: initial results at an infective endocarditis referral center. Circulation 2015; 132 (12) 1113-1126
- 30 Oberbach A, Friedrich M, Lehmann S. et al; CardiOmics group, Clinical Microbiology group, Bioinformatics group. Bacterial infiltration in structural heart valve disease. J Thorac Cardiovasc Surg 2019; (e-pub ahead of print) DOI: 10.1016/j.jtcvs.2019.02.019.
- 31 Oberbach A, Schlichting N, Friedrich M. et al; CardiOmics group, Clinical Microbiology group, Clinical Management group. Quantification of multiple bacteria in calcified structural valvular heart disease. Semin Thorac Cardiovasc Surg 2020; 32 (02) 255-263